Company Overview of Pulmatrix, Inc.
Pulmatrix, Inc. is a clinical stage biotechnology company. It focuses on developing therapies for the treatment of chronic respiratory diseases, including cystic fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company develops iSPERSE (inhaled small particles easily respirable and emitted), a drug delivery platform that enables drugs to be delivered in inhaled dry powders; and uses particle engineering to create dry powder formulations with various drug substances, such as small molecules, biologics, and multi-drug combinations. Its product pipeline includes PUR0200, a once daily inhaled bronchodilator for chronic obstructive pulmonary disease; and PUR...
99 Hayden Avenue
Lexington, MA 02421
Founded in 2003
Key Executives for Pulmatrix, Inc.
Chief Executive Officer and Director
Co-Founder and Chairman of the Scientific Advisory Board
Co-Founder, Director and Member of the Scientific Advisory Board
Chief Medical Officer and Senior Vice President
Compensation as of Fiscal Year 2014.
Pulmatrix, Inc. Key Developments
Ruthigen, Inc. and Pulmatrix, Inc. Appoint Robert Clarke as President and CEO
Mar 16 15
Ruthigen agreed to acquire Pulmatrix. Upon completion of the merger, Ruthigen will be renamed Pulmatrix. Pulmatrix President and CEO Robert Clarke will be appointed as the president and CEO of the combined company.
Pulmatrix, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015
Dec 19 14
Pulmatrix, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 . Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.
Pulmatrix, Inc. Announces Positive Results from Initial Stage of Phase IB Clinical Study of PUR0200 in COPD Patients
Oct 28 13
Pulmatrix, Inc. announced the completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule product from the company's novel iSPERSE™ inhaled dry powder technology. The first part of the Phase 1B clinical trial evaluated the safety, tolerability and the pharmacokinetic/pharmacodynamic profile of single ascending doses of PUR0200 in patients with moderate COPD. The first part of the Phase 1B study evaluated pharmacokinetics and pulmonary function after administration of four single ascending doses of PUR0200 in 24 patients with moderate COPD. All doses of PUR0200 were generally well tolerated and were associated with increases in lung function, as measured by peak and trough forced expiratory volume (FEV1) from baseline, and compared to placebo dosing. Pharmacokinetic assessments affirmed the effective lung delivery of PUR0200 and the iSPERSE platform and compared favorably to published data on lactose blend formulations. The data from the first part of the study will be used to inform dose selection for the second part of the study, a cross-over design study that starts this month and includes an active comparator arm. The study is targeted for completion in the first quarter of 2014 and data from both parts of the study will be presented at a future scientific meeting.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 13, 2015
March 13, 2015